ALFA Finder| Revenue growth | FY26 +6% YoY; Q4 ex-gRevlimid +15.3% YoY. |
|---|---|
| Margins | EBITDA margin at 20.4%; guided >21% for FY27. |
| Demand visibility | Sustained momentum in regulated markets; stable volumes. |
| Management confidence | Bullish on US $2bn target and Europe €1bn base. |
Growth
FY26 revenue grew 6% YoY (9.5% ex-gRevlimid); Q4 FY26 revenue reached ₹8,853cr with Net Profit up 2% to ₹921cr.
Outlook
FY27 EBITDA margin guided north of 21%. US business aiming for $2bn revenue milestone near-term via Lannett acquisition.
Risks
Higher operating costs from power/fuel; seasonality in US sales; geopolitical issues; pricing pressures in biosimilars.
Earnings Call filed with BSE, NSE: AUROPHARMA. Summary written with AI assistance from the document.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,823.20
- Market cap
- ₹1,05,892 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.1×Sector 43.7×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Business Update
Aurobindo Pharma disclosed that US FDA classified its Lannett facility inspection as Official Action Indicated (OAI). The company states there is no quantifiable financial or operational impact.
Aurobindo Pharma Acquisition Worth ₹29 Cr
Aurobindo's subsidiary Auropharm Overseas will buy 100% of Auro Pharma LLC, a Russian step-down subsidiary, for about Rs 29 crore cash. It is an internal group reorganisation.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Management Change
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
- Execution
- Five years from April 1, 2027
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Acquisition
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma Dividend
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.